SUBSCRIBE
SUBSCRIBE

Incyclix Bio

IN THE PRESS
Press Releases
Incyclix Bio Secures $11.25 Million Series B Extension to Advance the Phase 1/2 Clinical Trial of INX-315 in Patients with CDK4/6 Inhibitor Resistant ER+/HER2- Breast Cancer or CCNE1-Amplified Solid Tumors
August 25, 2025
 · 
2 min read
Press Releases
Incyclix Bio Granted U.S. FDA Fast Track Designation for INX-315 to Treat CCNE1-Amplified Platinum-Resistant/Refractory Ovarian Cancer
April 30, 2025
 · 
2 min read
Press Releases
Incyclix Bio Announces Publication in Nature Communications Highlighting Biomarkers of Response to CDK2 Inhibition
February 14, 2025
 · 
2 min read
Press Releases
Incyclix Bio Announces Interim Clinical Data from the Phase 1/2 Clinical Trial of INX-315 in Patients with CDK4/6 Inhibitor Resistant ER+/HER2- Breast Cancer or CCNE1-Amplified Solid Tumors
December 13, 2024
 · 
3 min read
Press Releases
Incyclix Bio Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate INX-315 in Combination with Verzenio® (abemaciclib) and Fulvestrant in HR+/HER2- Breast Cancer
November 18, 2024
 · 
2 min read
Press Releases
Incyclix Bio Announces Abstract Accepted for Presentation at 2024 San Antonio Breast Cancer Symposium
November 5, 2024
 · 
1 min read
Press Releases
Incyclix Bio Appoints Dr. Andrew Beelen as Vice President of Clinical Development
August 20, 2024
 · 
2 min read
Drug Development
Incyclix Bio Announces FDA Clearance of Investigational New Drug Application for INX-315 in Patients with Advanced or Metastatic Cancer
February 28, 2023
 · 
2 min read
Bio NC
Incyclix Bio Announces $30 Million Series B Financing Led by Boxer Capital
March 31, 2022
 · 
3 min read
JOBS